<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776567</url>
  </required_header>
  <id_info>
    <org_study_id>01/12</org_study_id>
    <nct_id>NCT01776567</nct_id>
  </id_info>
  <brief_title>Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms</brief_title>
  <acronym>APPOSE</acronym>
  <official_title>Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northern Hospital, Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northern Hospital, Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to directly compare the Cobalt Chromium platform
      everolimus-eluting stent, Xience Prime™, with the Platinum Chromium platform
      everolimus-eluting stent, Promus Element™, in relation to stent scaffolding shape, position
      with the heart blood vessel and extent of tissue coverage (at 6 months) using optical
      coherence tomography.

      Hypotheses:

        1. The alloy composition and strut design of a drug-eluting stent has a direct bearing on
           stent apposition measured using OCT.

        2. Stent design and alloy composition have a direct influence on radial support and
           scaffold shrinkage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Percent incomplete stent apposition using OCT of the CoCr-EES versus the PtCr-EES stent inflated to nominal pressure and following optimal post-dilatation. Stent length (mm) at implantation following nominal pressure and following post-dilatation</measure>
    <time_frame>Immediately following stent deployment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of uncovered stent struts</measure>
    <time_frame>6 mths post initial PCI procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean neointimal tissue thickness (microns)</measure>
    <time_frame>6 months post initial PCI Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent length (mm) measured using OCT</measure>
    <time_frame>6 months post initial PCI procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cobalt Chromium Everolimus-eluting stent (Xience Prime)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cobalt Chromium Everolimus-eluting stent (Xience Prime)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platinum Chromium Everolimus-eluting stent (Promus Element)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Platinum Chromium Everolimus-eluting stent (Promus Element)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus eluting stents</intervention_name>
    <arm_group_label>Cobalt Chromium Everolimus-eluting stent (Xience Prime)</arm_group_label>
    <arm_group_label>Platinum Chromium Everolimus-eluting stent (Promus Element)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Symptomatic coronary artery disease including patients with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation myocardial
             infarction

          3. Presence of one or more coronary artery stenosis &gt; 50% in a native coronary artery
             with a reference diameter ranging from 2.25 to 4.25 mm which can be covered with one
             or multiple stents

          4. No limitation to the number of treated lesions or number of vessels according to the
             randomization group

          5. De-novo native coronary disease with complex lesions involving: Bifurcations, chronic
             occlusions &gt; 3 months, lesions &gt; 20mm in length or moderately/heavily calcified
             lesions of any length

        Exclusion Criteria:

          1. Known intolerance to aspirin, clopidogrel, heparin, cobalt chromium, platinum
             chromium, everolimus, contrast material

          2. Acute ST-segment elevation myocardial infarction

          3. Type A lesion including vessel angulation &lt;45 degrees

          4. Bypass graft

          5. Inability to provide informed consent

          6. Pregnancy

          7. Planned surgery within 12 months of PCI unless dual antiplatelet therapy is maintained
             throughout the peri-surgical period

          8. Left ventricular ejection fraction &lt; 25%

          9. Serum creatinine &gt; 180mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Barlis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Barlis, MBBS MPH PHD FESC FRACP</last_name>
    <phone>+61 3 8405 8554</phone>
    <email>pbarlis@unimelb.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Concord Repatriation Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harry Lowe</last_name>
    </contact>
    <investigator>
      <last_name>Harry Lowe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darren Walters</last_name>
    </contact>
    <investigator>
      <last_name>Darren Walters</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Wong</last_name>
      <email>rita.wong@nh.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter Barlis, MBBS PHD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Whitbourn</last_name>
    </contact>
    <investigator>
      <last_name>Robert Whitbourn</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>August 2, 2014</last_update_submitted>
  <last_update_submitted_qc>August 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northern Hospital, Australia</investigator_affiliation>
    <investigator_full_name>A/Prof. Peter Barlis</investigator_full_name>
    <investigator_title>Interventional Cardiologist</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>stents</keyword>
  <keyword>optical imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Cobalt</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

